Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Biogen Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017
Cash and cash equivalents	3,675,600)	2,646,600)	1,749,300)	2,261,400)	1,541,800)	1,742,000)	1,217,500)	1,331,200)	2,224,800)	2,384,900)	2,591,300)	2,913,700)	2,343,900)	1,723,400)	2,243,200)	1,224,600)	2,386,700)	1,250,200)	4,108,000)	1,573,800)	1,548,100)	1,169,500)	924,000)
Marketable securities	1,235,500)	2,151,300)	2,002,400)	1,541,100)	1,413,300)	1,308,800)	1,320,000)	1,278,900)	1,355,000)	1,942,700)	1,269,100)	1,562,200)	2,093,500)	1,228,800)	1,665,800)	2,313,400)	2,041,700)	1,974,000)	1,808,000)	2,115,200)	1,960,200)	1,723,500)	1,956,200)
Accounts receivable, net	1,568,800)	1,567,600)	1,632,000)	1,549,400)	1,723,000)	1,688,000)	1,854,300)	1,913,800)	2,024,900)	2,133,600)	2,092,600)	1,880,500)	1,933,500)	1,959,600)	2,088,900)	1,958,500)	2,017,300)	1,951,000)	1,939,200)	1,787,000)	1,567,500)	1,630,200)	1,501,500)
Due from anti-CD20 therapeutic programs	415,400)	435,900)	389,400)	412,300)	400,000)	422,200)	369,800)	413,500)	527,200)	441,100)	511,600)	590,200)	582,300)	557,500)	527,100)	526,900)	508,400)	481,900)	553,500)	532,600)	518,000)	502,900)	324,500)
Inventory	1,375,000)	1,294,200)	1,215,400)	1,351,500)	1,347,900)	1,254,800)	1,171,800)	1,068,600)	1,027,700)	952,700)	858,800)	804,200)	751,800)	776,700)	770,200)	929,900)	916,600)	931,700)	890,800)	902,700)	1,007,200)	936,500)	921,600)
Assets held for sale	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	683,400)	682,000)	—)	—)	—)	—)	—)	—)	—)	—)
Other current assets	1,495,500)	1,645,300)	927,400)	740,800)	736,300)	767,900)	786,100)	881,100)	683,500)	638,800)	683,800)	631,000)	743,200)	980,400)	965,400)	687,600)	848,300)	843,300)	895,900)	962,000)	967,000)	1,146,100)	1,231,900)
Current assets	9,765,800)	9,740,900)	7,915,900)	7,856,500)	7,162,300)	7,183,700)	6,719,500)	6,887,100)	7,843,100)	8,493,800)	8,007,200)	8,381,800)	8,448,200)	7,909,800)	8,942,600)	7,640,900)	8,719,000)	7,432,100)	10,195,400)	7,873,300)	7,568,000)	7,108,700)	6,859,700)
Marketable securities	860,300)	1,102,900)	1,001,600)	892,000)	968,300)	915,100)	821,900)	772,100)	1,009,800)	922,800)	969,500)	1,408,100)	1,813,900)	1,309,300)	1,372,700)	1,375,900)	1,244,500)	1,160,200)	1,200,200)	3,057,300)	3,062,000)	2,632,700)	2,825,200)
Property, plant and equipment, net	3,266,400)	3,355,100)	3,372,800)	3,416,400)	3,410,700)	3,442,200)	3,438,300)	3,411,500)	3,359,900)	3,330,700)	3,281,600)	3,247,300)	3,138,100)	3,077,500)	3,013,800)	3,601,200)	3,538,900)	3,409,000)	3,334,700)	3,182,400)	2,995,900)	2,827,600)	2,610,900)
Operating lease assets	424,500)	321,100)	359,000)	375,400)	389,100)	402,500)	414,500)	433,300)	434,200)	436,200)	422,000)	427,000)	422,000)	434,400)	447,800)	—)	—)	—)	—)	—)	—)	—)	—)
Intangible assets, net	2,008,900)	2,075,300)	2,150,800)	2,221,300)	2,286,800)	2,385,000)	2,988,100)	3,084,300)	3,323,600)	3,383,800)	3,446,900)	3,527,400)	3,392,400)	3,681,300)	3,056,200)	3,120,000)	3,379,000)	3,661,300)	3,794,500)	3,879,600)	4,019,400)	4,051,300)	4,103,900)
Goodwill	5,741,200)	5,749,600)	5,758,000)	5,761,100)	5,760,500)	5,763,900)	5,763,100)	5,762,100)	5,755,700)	5,751,000)	5,752,000)	5,757,800)	5,746,100)	5,749,200)	5,639,700)	5,706,400)	5,440,100)	5,170,300)	4,907,800)	4,632,500)	4,127,500)	3,870,400)	3,611,700)
Deferred tax asset	1,174,500)	1,235,700)	1,288,800)	1,415,100)	1,810,400)	1,849,900)	1,286,300)	1,369,500)	1,372,900)	1,710,200)	3,109,400)	3,232,100)	3,284,500)	2,820,100)	2,074,400)	2,153,900)	2,160,900)	2,217,900)	2,277,400)	595,900)	—)	—)	—)
Investments and other assets	1,612,600)	1,500,800)	1,767,500)	1,939,500)	2,018,600)	2,528,100)	2,423,000)	2,899,000)	1,834,900)	1,483,300)	1,130,600)	1,252,800)	1,238,800)	1,306,000)	1,898,300)	1,690,600)	1,009,800)	902,100)	380,100)	431,600)	1,300,400)	1,268,300)	1,184,500)
Long-term assets	15,088,400)	15,340,500)	15,698,500)	16,020,800)	16,644,400)	17,286,700)	17,135,200)	17,731,800)	17,091,000)	17,018,000)	18,112,000)	18,852,500)	19,035,800)	18,377,800)	17,502,900)	17,648,000)	16,773,200)	16,520,800)	15,894,700)	15,779,300)	15,505,200)	14,650,300)	14,336,200)
Total assets	24,854,200)	25,081,400)	23,614,400)	23,877,300)	23,806,700)	24,470,400)	23,854,700)	24,618,900)	24,934,100)	25,511,800)	26,119,200)	27,234,300)	27,484,000)	26,287,600)	26,445,500)	25,288,900)	25,492,200)	23,952,900)	26,090,100)	23,652,600)	23,073,200)	21,759,000)	21,195,900)

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Biogen Inc. current assets increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Property, plant and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Biogen Inc. property, plant and equipment, net decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Long-term assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Biogen Inc. long-term assets decreased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Biogen Inc. total assets increased from Q1 2022 to Q2 2022 but then slightly decreased from Q2 2022 to Q3 2022.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Biogen Inc. cash and cash equivalents increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.
Marketable securities	Amount of investment in marketable security, classified as current.	Biogen Inc. marketable securities increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Biogen Inc. accounts receivable, net decreased from Q1 2022 to Q2 2022 but then slightly increased from Q2 2022 to Q3 2022.
Inventory	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Biogen Inc. inventory increased from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Biogen Inc. (NASDAQ:BIIB)

Balance Sheet: AssetsQuarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data